Nonoccupational HIV post-exposure prophylaxis: A 10-year retrospective analysis

HIV Medicine

Volumn 11, Issue 9, 2010, Pages 584-592

  Tissot, F ^a   Erard, V ^a   Dang, T ^a   Cavassini, M ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Community; HIV; Nonoccupational; Out patient; Post exposure prophylaxis

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; LOPINAVIR; NELFINAVIR; RITONAVIR; ZIDOVUDINE;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PANCREATITIS; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; SEROCONVERSION; SEXUAL CRIME; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTI-HIV AGENTS; CONTACT TRACING; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; MALE; MIDDLE AGED; NEEDLE SHARING; NEEDLESTICK INJURIES; PATIENT ACCEPTANCE OF HEALTH CARE; POST-EXPOSURE PROPHYLAXIS; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS; SWITZERLAND; UNSAFE SEX; YOUNG ADULT;

EID: 77956415757     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00826.x     Document Type: Article

References (28)

1. Otten RA, Smith DK, Adams DR. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol 2000, 74:9771-9775.
2. Tsai CC, Emau P, Follis KE. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998, 72:4265-4273.
3. Connor EM, Sperling RS, Gelber R. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 study group. N Engl J Med 1994, 331:1173-1180.
4. Sperling RS, Shapiro DE, Coombs RW. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996, 335:1621-1629.
5. Case-control study of HIV seroconversion in health care workers after percutaneous exposure to HIV-infected blood: France, United Kingdom and United States, January 1988-August 1994. Morb Mortal Wkly Rep 1995, 44:929-933. Centers for Disease Control.
6. Cardo DM, Culver DH, Ciesielski CA. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for disease control and prevention needlestick surveillance group. N Engl J Med 1997, 337:1485-1490.
7. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States. Morb Mortal Wkly Rep 2005, 54((no. RR-2)):1-20. Centers for Disease Control.
8. Katz MH, Gerberding JL. Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection drug use. N Engl J Med 1997, 336:1097-1100.
9. Bernasconi E, Jost J, Ledergerber B. Antiretroviral prophylaxis for community exposure to the human immunodeficiency virus in Switzerland, 1997-2000. Swiss Med Wkly 2001, 131:433-437.
10. Rey D, Bendiane MK, Moatti JP. Post-exposure prophylaxis after occupational and non-occupational exposures to HIV: an overview of the policies implemented in 27 European countries. AIDS Care 2000, 12:695-701. for the European Study Group on HIV Testing Policies and Practices in Europe.
11. Gostin LO, Lazzarini Z, Alexander D. HIV testing, counseling, and prophylaxis after sexual assault. JAMA 1994, 271:1436-1444.
12. Wiebe ER, Comay SE, McGregor M, Ducceschi S. Offering HIV prophylaxis to people who have been sexually assaulted: 16 months' experience in a sexual assault service. CMAJ 2000, 162:641-645.
13. Teixeira Garcia M, Moralez Figueiredo M, Moretti ML. Postexposure prophylaxis after sexual assaults: a prospective cohort study. Sex Trans Dis 2005, 32:214-219.
14. Preliminary recommendations for HIV post-exposure prophylaxis outside the medical setting. Bull OFSP 1997, 50:4-6. Swiss Federal Office of Public Health.
15. Recommendations for HIV post-exposure prophylaxis outside the medical setting - update 2006. Bull OFSP 2006, 36:712-715. Swiss Federal Office of Public Health.
16. Kahn JO, Martin JN, Roland ME. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP study. J Infect Dis 2001, 183:707-714.
17. Poyten IM, Smith DE, Cooper DA. The public health impact of widespread availability of nonoccupational postexposure prophylaxis against HIV. HIV Med 2007, 8:374-381.
18. Martin JN, Roland ME, Neilands TB. Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS 2004, 18:787-792.
19. Schechter M, Do Lago RF, Mendelsohn AB. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr 2004, 35:519-525.
20. Roland ME, Martin JN, Grant RM. Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: identification and characterization of the source of exposure. J Infect Dis 2001, 184:1608-1612.
21. Myles JE, Hirozawa A, Katz MH. Postexposure prophylaxis for HIV after sexual assault. JAMA 2000, 284:1516-1518.
22. Siika AM, Nyandiko WM, Mwangi A. The structure and outcomes of a HIV postexposure prophylaxis program in a high HIV prevalence setup in western Kenya. J Acquir Immune Defic Syndr 2009, 51:47-53.
23. Pinkerton SD, Martin JN, Roland ME. Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus. Arch Intern Med 2004, 164:46-54.
24. Roland ME, Neilands TB, Krone MR. Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis 2005, 41:1507-1513.
25. Almeda J, Casabona BJ, Simon B. http://www.eurosurveillance.org/em/v09n06/0906-223.asp, Proposed recommendations for the management of HIV post-exposure prophylaxis after sexual, injecting drug or other exposures in Europe. Available at, (accessed 2 December 2008)
26. Greub G, Gallant S, Zurn P. Spare non-occupational HIV post-exposure testing by active contacting and testing of the source person. AIDS 2002, 16:1171-1176.
27. http://www.bag.admin.ch, Swiss Federal Office of Public Health., Characteristics of HIV epidemics in Switzerland in 2008. Available at, (accessed 21 April 2009)
28. Giulieri S, Schiffer V, Yerly S. The trap: professional exposure to human immunodeficiency virus antibody-negative blood with high viral load. Arch Intern Med 2007, 167:2524-2526.